USPTO issues memorandum in response to CellzDirect and Sequenom
The USPTO tells examiners the Federal Circuit’s CellzDirect ruling “highlighted several important points” but says its subject matter eligibility guidance and training examples are already consistent with it
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
